Purpose: To compare the results of laser treatment and intravitreal ranibizumab injections in patients with DME consistent with the level of VEGF A in tear fluid.

Methods: The progress of visual acuity, retinal thickness and light sensivity after laser treatment and ranibizumab intravitreal injection has been assessed.

Results: One month after the treatment the main effect of laser was the decrease of retinal thickness, whereas after ranibizumab — the increase of visual acuity. The significant decrease of VEGF A level in tear fluid was found only in ranibizumab group.

Conclusion: Laser treatment of DME leads to permanent retinal thickness decrease and insignificant functional improvement in comparison with ranibizumab IV injection, which leads to temporary morphological and functional improvement.